Short-term survivors with brain metastases have modest benefits from focal and systemic therapies and remain frequent despite improving treatment landscape

M. Czogalla(Leipzig University), Clemens Seidel(Leipzig University), Peter Hambsch(Leipzig University), Sabine Klagges(University Hospital Leipzig), Nils Gleim(Leipzig University), Johannes Wach(Leipzig University), Alonso Barrantes‐Freer(Universitätsmedizin Göttingen), Jiřı́ Stöhr(Leipzig University), Thomas Kuhnt(Leipzig University), Nils H. Nicolay(University Hospital Leipzig), Franziska Nägler(Leipzig University), Kirsten Papsdorf(Leipzig University)
Clinical and Translational Radiation Oncology
January 10, 2025
10.1016/j.ctro.2025.100919
Cited by 2

Related Papers

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
|The Lancet|2019|581
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12
|Journal of Clinical Oncology|2019|550
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
|JAMA Oncology|2021|369
Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas
|International Journal of Radiation Oncology*Biology*Physics|2000|218
Anemia in cervical cancers: Impact on survival, patterns of relapse, and association with hypoxia and angiogenesis
|International Journal of Radiation Oncology*Biology*Physics|2003|197